Avinger Files US Application For New Pantheris In-Stent Restenosis Indication
Avinger Inc (NASDAQ:AVGR) has submitted a 510(k) application to the FDA for a new Pantheris clinical indication for the treatment of…
Puma Biotech’s Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer
Health Canada has approved Puma Biotechnology Inc’s (NASDAQ:PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who…
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc.
Adial Pharmaceuticals Says Phase 3 ONWARD Trial Meets Screening Target, Nears Enrollment Completion
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the Company has made significant progress on
General Electric Says GE Healthcare, SOPHiA GENETICS To Collaborate To Match Treatments To Multimodal Patient Data And Cancer Type
GE Healthcare and SOPHiA GENETICS today announced that they have signed a letter of intent to collaborate on advancing cancer care, with the goal of better targeting and matching treatments to each
ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7
Following consultations with the FDA, ChemoCentryx Inc (NASDAQ:CCXI) filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil…
Ayala Pharmaceuticals Says To Present At Ladenburg Thalmann Healthcare Conference
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced
Heron Therapeutics Announces 340B Prime Vendor Contract With Apexus For ZYNRELEF
Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient
ChemoCentryx Shares Tick Higher; Co Announces Filing Of Amendment To NDA Submission, Extension Of The PDUFA Review Period For Avacopan In Treatment Of ANCA-Associated Vasculitis
ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of